# Deferoxamine for the Treatment of Hemochromatosis

> **NCT00001203** · — · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 151 (actual)

## Conditions studied

- Diabetes Mellitus
- Heart Disease
- Hemochromatosis
- Thalassemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT00001203
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 1985-04-22
- **Primary completion:** —
- **Final completion:** 2015-11-09
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2019-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001203, "Deferoxamine for the Treatment of Hemochromatosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00001203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*